What is it about?
This study applies cost-effectiveness modelling to estimate the appropriate pricing of the new antiviral agents for viral hepatitis C in Hong Kong. The cost-effectiveness is compared to traditional treatment options with peg interferon and ribavirin therapy.
Featured Image
Why is it important?
As pricing of drugs are different in different countries, local cost-effectiveness analysis is essential to plan healthcare budgeting. This study serves can serve as a guidance for the local government to plan the reimbursement strategy of the highly effective antiviral treatment for viral hepatitis C in Hong Kong. It can also serve as a model for other countries to build their own cost-effectiveness models.
Perspectives
The new antiviral agents for viral hepatitis C are highly effective yet very expensive. This paper shows how local government should consider her reimbursement policy; not just based on the cost of the drugs but the future cost for treatment of hepatitis C related complications such as liver cirrhosis and liver cancer.
Prof Henry LY Chan
Chinese University of Hong Kong
Read the Original
This page is a summary of: Cost-effectiveness of the highly effective direct-acting antivirals in the treatment of chronic hepatitis C in Hong Kong, Journal of Gastroenterology and Hepatology, April 2017, Wiley,
DOI: 10.1111/jgh.13638.
You can read the full text:
Contributors
The following have contributed to this page
